VTCN1 and colorectal carcinoma: Although we have not yet elucidated the exact mechanisms by which SH3TC2 participates in the immunosuppression of CRC and the regulation of VTCN1 by SH3TC2, our bioinformatics results provide the first clue to further explore the role of SH3TC2 in CRC immunotherapy.